UK markets open in 6 hours 33 minutes

Atea Pharmaceuticals, Inc. (AVIR)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
3.7000-0.0300 (-0.80%)
At close: 04:00PM EDT
3.6500 -0.05 (-1.35%)
After hours: 05:04PM EDT

Atea Pharmaceuticals, Inc.

225 Franklin Street
Suite 2100
Boston, MA 02110
United States
857 284 8891
https://ateapharma.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees75

Key executives

NameTitlePayExercisedYear born
Dr. Jean-Pierre Sommadossi Ph.D.Founder, Chairman, CEO & President1.1MN/A1956
Ms. Andrea J. Corcoran J.D.CFO, Executive VP of Legal & Secretary732.45kN/A1962
Mr. John F. VavrickaChief Commercial Officer581.11kN/A1964
Dr. Janet M. J. Hammond M.D., Ph.D.Chief Development Officer817.16kN/A1961
Dr. Maria Arantxa Horga M.D.Chief Medical Officer695.85kN/A1969
Mr. Wayne Foster CPAExecutive VP of Finance & Chief Accounting OfficerN/AN/A1969
Ms. Jonae R. BarnesSenior Vice President of Investor Relations & Corporate CommunicationsN/AN/AN/A
Mr. Ariyapadi N. KrishnarajVice President of MarketingN/AN/AN/A
Mr. Adel Moussa Ph.D.Executive Vice President of ChemistryN/AN/AN/A
Mr. Xiao-Jian Zhou Ph.D.Executive Vice President of Early Stage DevelopmentN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Corporate governance

Atea Pharmaceuticals, Inc.’s ISS governance QualityScore as of 1 April 2024 is 9. The pillar scores are Audit: 3; Board: 10; Shareholder rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.